Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.

Acta pharmacologica Sinica - 1 Feb 2019

Gao Ming-Zhao, Wang Hong-Bin, Chen Xiang-Ling, Cao Wen-Ting, Fu Li, Li Yun, Quan Hai-Tian, Xie Cheng-Ying, Lou Li-Guang

Abstract excerpt

BRAF and MEK inhibitors have shown remarkable clinical efficacy in BRAF-mutant melanoma; however, most patients develop resistance, which limits the clinical benefit of these agents. In this study, we found that the human melanoma cell clones, A375-DR and A375-TR, with acquired resistance to BRAF inhibitor dabrafenib and MEK inhibitor trametinib, were cross resistant to other MAPK pathway inhibitors. In these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 29777202
DOI: 10.1038/s41401-018-0020-z
PMCID: PMC6329746

Genes

BRAF
CDK6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.PMID 29777202Read ↗

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinaseSemantic proximity Read ↗

Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasionSemantic proximity Read ↗

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.Semantic proximity Read ↗

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.Semantic proximity Read ↗

Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cellsSemantic proximity Read ↗

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in CancerSemantic proximity Read ↗

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.Semantic proximity Read ↗

RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1Semantic proximity Read ↗

Proteasomal downregulation of the pro-apoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanomaSemantic proximity Read ↗

Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress.Semantic proximity Read ↗

Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancersSemantic proximity Read ↗

The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.